Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma

Renal cell carcinoma (RCC), especially clear cell RCC, is generally considered an immunotherapy-responsive cancer. Recently, the prognosis for patients with locally advanced and metastatic RCC has significantly improved with the regulatory approvals of anti-PD-1/PD-L1/CTLA-4 immune checkpoint inhibi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Albert Jang, Jake N. Lichterman, Jeffrey Y. Zhong, Jonathan E. Shoag, Jorge A. Garcia, Tian Zhang, Pedro C. Barata
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis Group 2023-12-01
Saila:Human Vaccines & Immunotherapeutics
Gaiak:
Immunotherapy
gut microbiota
cytokine
interleukin
immune checkpoint inhibitor
vaccine
Sarrera elektronikoa:https://www.tandfonline.com/doi/10.1080/21645515.2023.2276629
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak